EcoDrugPlus

Endothelin Receptor Ba

Ensembl ID : ENSIPUG00000012775
Gene Symbol: EDNRBA
4 Cross references
196 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSIPUG00000004480
Gene Symbol: EDNRAA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSIPUG00000000765
Gene Symbol: EDNRAB
4 Cross references
197 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSIPUG00000006483
Gene Symbol: EZH2
3 Cross references
238 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSIPUG00000022585
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSIPUG00000004113
Gene Symbol: EPHB4B
4 Cross references
169 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSIPUG00000010294
Gene Symbol: EGFRA
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSIPUG00000004085
Gene Symbol: EPHX2
3 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSIPUG00000020034
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSIPUG00000023381
Gene Symbol: ERBB3
3 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSIPUG00000019692
Gene Symbol: ERBB3B
3 Cross references
206 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSIPUG00000006935
Gene Symbol: ERBB4
4 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).